New vaccine aims to halt ovarian cancer recurrence detected in blood
NCT ID NCT07495124
First seen Jun 25, 2026 · Last updated Jul 14, 2026 · Updated 3 times
Summary
This phase II trial tests whether an IGFBP-2 vaccine, given after one dose of carboplatin, can stop ovarian cancer from growing in patients whose recurrence is detected only through a blood test. The vaccine helps the immune system target cancer cells, while carboplatin primes the immune response. The study includes 26 participants with ovarian, fallopian tube, or primary peritoneal cancer who have completed platinum-based chemotherapy.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- IGFBP-2 vaccine (DNA vaccine) plus carboplatin
- What this could lead to
- If it works, this could offer a new way to delay or prevent ovarian cancer from growing after it is first detected in the blood, potentially extending time without visible disease.
- What could go wrong
- This is a small, early-phase trial with only 26 participants, so results may not apply to everyone. The vaccine may not trigger a strong enough immune response, and side effects from carboplatin are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FALLOPIAN TUBE CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fred Hutch/University of Washington Cancer Consortium
Seattle, Washington, 98109, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Experimental pill takes on Hard-to-Treat ovarian cancer
- Targeted drug hunts down cancer cells in advanced bladder cancer trial
- Radiation boost may Re-Sensitize ovarian cancer to PARP inhibitors
- New PET tracer could spot cancers that standard scans overlook
- Can a mesh shield ovarian cancer patients from painful hernias?
- Targeted Antibody-Drug could shrink Hard-to-Treat ovarian cancers